15-min delayed · Aug 26, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Neurosense Therapeutics Ltd, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $3.00 to $14.00 (about 4.7x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $8.50 sits 1974% above the current $0.41. The rating mix has held broadly steady over recent months.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Neurosense Therapeutics Ltd.
As of Aug, 2 of 2 firms rate NRSN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NRSN EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 1 analysts
Next period, 1 analysts expect Neurosense Therapeutics Ltd to earn — a share (range — – —), versus — a year earlier. Full-year consensus is $-0.40, growing to $-0.82 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $4.0M next year.
Top analysts covering Neurosense Therapeutics Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NRSN.
#1
Jason Kolbert
D. Boral Capital · Rank #407
Buy
$14.00+3315.5% to target
Overall win rate
22%
+ Follow
#2
James Molloy
Alliance Global Partners · Rank #445
Buy
$7.50+1729.7% to target
Overall win rate
25%
+ Follow
#3
NR
Naz Rahman
Maxim Group
Hold
No targeton NRSN
Coverage
—
+ Follow
#4
Boobalan Pachaiyappan
Roth Capital
Buy
$3.00+631.9% to target
Coverage
—
+ Follow
NRSN stock forecast FAQ
What is NRSN's average 12-month price target?+
The 2 analysts with a live target average $8.50 for Neurosense Therapeutics Ltd over the next 12 months, ranging from a $14.00 high to a $3.00 low.
Is NRSN stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for NRSN?+
The Street-high target is $14.00 (D. Boral Capital), and the Street-low is $3.00 (Roth Capital). The average of all 2 active targets is $8.50.
How many Wall Street analysts cover NRSN?+
2 analysts have an active rating on Neurosense Therapeutics Ltd, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering NRSN?+
Among analysts who currently cover NRSN, Jason Kolbert of D. Boral Capital has the strongest overall Quantellect track record (Rank #407). Their current call is Buy with a $14.00 target.
What is Neurosense Therapeutics Ltd's projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 1 analysts. Full-year EPS is projected at $-0.40, rising to $-0.82 the following year.
How much revenue is Neurosense Therapeutics Ltd expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $4.0M next year.
Have analysts been upgrading or downgrading NRSN lately?+
As of Aug, 2 of 2 firms rate NRSN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NRSN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
